Significant Ownership of Sofinnova Crossover I
- Signature - Title
- /s/ Antoine Papiernik - Managing Partner
- Location
- Paris, France
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Sofinnova Crossover I.
Follow Filing Activity
Follow Sofinnova Crossover I and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of Sofinnova Crossover I
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| IVA | Inventiva, S.A. | Ordinary Shares, nominal value EUR0.01 per share | 8.6% | $108,981,346 | +$64,487,273 | 19,086,050 | +145% | Sofinnova Partners SAS, a French corporation | 31 Dec 2025 |
| ABVX | Abivax S.A. | Ordinary Shares, par value EUR0.01 per share | 7.7% | $863,002,246 | -$269,710,200 | 6,399,478 | -24% | Sofinnova Crossover I SLP | 12 Jan 2026 |
Schedules 13D/G Reported by Sofinnova Crossover I:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.